Theravance Biopharma Inc. (TBPH) Shares Bought by BNP Paribas Arbitrage SA
BNP Paribas Arbitrage SA raised its position in shares of Theravance Biopharma Inc. (NASDAQ:TBPH) by 110.2% during the third quarter, Holdings Channel reports. The fund owned 3,008 shares of the biopharmaceutical company’s stock after buying an additional 1,577 shares during the period. BNP Paribas Arbitrage SA’s holdings in Theravance Biopharma were worth $109,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of TBPH. Teacher Retirement System of Texas increased its stake in shares of Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,401 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 192 shares during the last quarter. Bellevue Group AG acquired a new stake in shares of Theravance Biopharma during the first quarter worth approximately $215,000. Paloma Partners Management Co acquired a new stake in shares of Theravance Biopharma during the second quarter worth approximately $255,000. Finally, OMERS ADMINISTRATION Corp increased its stake in shares of Theravance Biopharma by 21.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 13,828 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 2,419 shares during the last quarter. 69.89% of the stock is owned by institutional investors.
Theravance Biopharma Inc. (NASDAQ:TBPH) opened at 29.03 on Friday. The stock has a 50 day moving average price of $33.14 and a 200-day moving average price of $25.33. Theravance Biopharma Inc. has a 12-month low of $12.87 and a 12-month high of $38.92. The company’s market capitalization is $1.39 billion.
Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.01. Theravance Biopharma had a negative return on equity of 70.79% and a negative net margin of 471.82%. Equities analysts predict that Theravance Biopharma Inc. will post ($4.03) EPS for the current fiscal year.
A number of brokerages recently commented on TBPH. Robert W. Baird downgraded Theravance Biopharma from a “neutral” rating to an “underperform” rating and increased their price target for the company from $19.00 to $24.00 in a research report on Wednesday. Zacks Investment Research raised Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday. Evercore ISI started coverage on Theravance Biopharma in a report on Monday, August 29th. They set a “buy” rating and a $41.00 price objective for the company. Leerink Swann reissued a “buy” rating and set a $31.00 price objective on shares of Theravance Biopharma in a report on Tuesday, August 9th. Finally, Guggenheim reissued a “positive” rating and set a $40.00 price objective on shares of Theravance Biopharma in a report on Monday, September 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Theravance Biopharma currently has a consensus rating of “Hold” and a consensus target price of $35.40.
In related news, SVP Brett K. Haumann sold 4,491 shares of the business’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $27.99, for a total value of $125,703.09. Following the completion of the transaction, the senior vice president now directly owns 188,293 shares in the company, valued at approximately $5,270,321.07. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Bradford J. Shafer sold 49,122 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the completion of the transaction, the executive vice president now owns 241,686 shares of the company’s stock, valued at $6,636,697.56. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc. (NASDAQ:TBPH).
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.